Department of General Surgery, The 323th Hospital of PLA, Xi'an 710054, China.
Diagn Pathol. 2013 Jun 21;8:102. doi: 10.1186/1746-1596-8-102.
Involvements of microRNA-22 (miR-22) in cancer development have attracted much attention, but its role in tumorigenesis of gastric cancer is still largely unknown. Therefore, the aim of this study was to investigate the expression patterns and clinical implications of miR-22 in gastric cancer.
Quantitative RT-PCR was performed to evaluate the expression levels of miR-22 in 98 pairs of gastric cancer and normal adjacent mucosa.
Compared with normal adjacent mucosa, miR-22 expression was significantly downregulated in gastric cancer tissues (P < 0.001). Of 98 patients with gastric cancer, 58 (59.2%) were placed in the low miR-22 expression group and 40 (40.8%) were placed in the high miR-22 expression group. In addition, tumors with low miR-22 expression had greater extent of lymph node metastasis (P = 0.02) and distant metastasis (P = 0.01), and were at a worse stage (P = 0.01) than the tumors with high miR-22 expression. Moreover, the gastric cancer patients with low miR-22 expression had shorter overall survival than those with high miR-22 expression (P = 0.03). MiR-22, determined by multivariate analysis, was an independent prognostic factor for patients with gastric cancer.
Our data offer the convincing evidence that the reduced expression of miR-22 was significantly associated with malignant development of gastric cancer and may be a novel prognostic marker of this disease. miR-22 might have potentials in the application of cancer therapy for patients with gastric cancer.
miR-22 在癌症发展中的作用引起了广泛关注，但它在胃癌发生中的作用在很大程度上仍不清楚。因此，本研究旨在探讨 miR-22 在胃癌中的表达模式及其临床意义。
采用定量 RT-PCR 检测 98 对胃癌组织及其癌旁正常组织中 miR-22 的表达水平。
与癌旁正常组织相比，miR-22 在胃癌组织中表达显著下调（P<0.001）。98 例胃癌患者中，58 例（59.2%）患者 miR-22 低表达，40 例（40.8%）患者 miR-22 高表达。此外，miR-22 低表达的肿瘤具有更大程度的淋巴结转移（P=0.02）和远处转移（P=0.01），且处于更差的分期（P=0.01），而 miR-22 高表达的肿瘤则相反。此外，miR-22 低表达的胃癌患者总生存期较 miR-22 高表达的患者更短（P=0.03）。多因素分析显示，miR-22 是胃癌患者的独立预后因素。
本研究数据提供了令人信服的证据，表明 miR-22 的下调表达与胃癌的恶性发展显著相关，可能是该疾病的一种新的预后标志物。miR-22 可能在胃癌患者的癌症治疗中有应用潜力。
